Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First‐Line Chemotherapy
Thoracic Cancer · 2025
DOI: 10.1111/1759-7714.15522 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Hohyung Nam und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, Catholic University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Membrane Proteins, Lung Neoplasms, Intracellular Signaling Peptides and Proteins. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Small cell lung cancer (SCLC) is known for its high proliferative rate and poor prognosis. Although Delta‐like ligand 3 (DLL3) is specifically expressed on the surface of SCLC, the association of DLL3 with prognosis in SCLC remains uncertain. Hence, we aimed to evaluate prognostic role of DLL3 in extensive stage of SCLC treated with first‐line chemotherapy. Materials and Methods A total of 54 patients with extensive stage of SCLC (ES‐SCLC) who were treated with first‐line chemotherapy were included for our analysis. In addition, tissue specimen should be available for immuno‐histochemical staining for DLL3, and their clinico‐pathologic data, including progression‐free survival (PFS) and overall survival (OS), were obtained. DLL3 expression and the percentage of tumor cells with DLL3 positive among total cancer cells were analyzed microscopically and DLL3 high and DLL3 low were defined as the percentage of DLL3 positive tumor cells versus total cancer cells ≧ 75% and < 75%, respectively.
Results
DLL3 expression was not associated with any of the clinico‐pathological characteristics such as age at diagnosis, sex, response to first‐line chemotherapy, second‐line chemotherapy (Yes or No), and number of metastatic sites. However, response to first‐line chemotherapy and number of metastatic sites were correlated to PFS, while DLL3 expression and number of metastatic sites were correlated to OS.
Conclusion
DLL3 was highly expressed in SCLC, and not associated with any clinico‐pathological characteristics. In survival outcome, DLL3 was correlated with worse OS, which suggests the prognostic role of DLL3 in ES‐SCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, Catholic University, Seoul, Republic of Korea.
- Department of Pathology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea.
- Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Department of Hematology-Oncology, Division of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea.
- Center of Evidence-Based Medicine, Institute of Convergence Science, Yonsei University, Seoul, Republic of Korea.
ORCID-Profile: Seungtaek Lim
Zitieren
APA
Nam, H., Jung, S. H., Lee, J. B., Kong, J. H., & Lim, S. (2025). Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First‐Line Chemotherapy. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15522
Vancouver
Nam H, Jung SH, Lee JB, Kong JH, Lim S. Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First‐Line Chemotherapy. Thoracic Cancer. 2025. doi:10.1111/1759-7714.15522
BibTeX
@article{Nam2025,
author = {Nam, Hohyung and Jung, Soon-Hee and Lee, Jii Bum and Kong, Jee Hyun and Lim, Seungtaek},
title = {Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First‐Line Chemotherapy},
journal = {Thoracic Cancer},
year = {2025},
doi = {10.1111/1759-7714.15522}
}
EUVIMED